Incog will add a second filling line to support the burgeoning syringe and cartridge filling capacity.

Shreeyashi Ojha, Reporter

February 21, 2024

1 Min Read
DepositPhotos/kchungtw

Contract development and manufacturing organization (CDMO) Incog will add ‘Optima MultiUse production filling line,’ investing $75 million in a 90,000 square-foot facility at its site in Fishers, Indiana. 

According to the CDMO, this expansion will be completed in Q2 of 2025. It aims to provide an additional 100 million units of syringe and cartridge filling capacity, and with this development, Incog BioPharma’s overall filling capacity will reach 140 million units annually. This will complement recently added automated visual inspection capabilities of the CDMO.

“We are a CDMO focused on creating a new standard of performance within our space,” said Cory Lewis, CEO of Incog. “We are investing proactively in the equipment and people necessary to create a better customer experience. Simply put, we are committed to taking the steps necessary to give meaning to our words.”Through this expansion the firm will provide sterile injectable manufacturing to its customers. With this expansion in place, the CDMO aims to “to support auto-injector device assembly services.”“From the beginning, we have had a big vision for what impact INCOG could make in the CDMO space. We’ve assembled a team with the experience and skill set to bring high-value sterile injectable drugs to the market with quality and speed,” said Lewis. “Seeing our capabilities and capacity expand when our partners need it most is exciting. We’re looking forward to the new partnerships and programs we plan to support in the coming year and beyond.” Incog did not respond when contacted by this publication.

About the Author(s)

Shreeyashi Ojha

Reporter, BioProcess Insider

Journalist covering the manufacturing and processing sectors for biopharmaceuticals globally.  

Originally from India, I am a Londoner at heart. I have recently graduated from Goldsmiths, University of London.  

Feel free to reach out to me at: [email protected].

You May Also Like